Zurcher Kantonalbank Zurich Cantonalbank Lowers Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,700 shares of the company's stock after selling 144,336 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Ginkgo Bioworks were worth $30,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Algert Global LLC bought a new stake in shares of Ginkgo Bioworks in the second quarter worth about $36,000. Wellington Wealth Strategies LLC. purchased a new position in shares of Ginkgo Bioworks during the second quarter valued at approximately $41,000. Thoroughbred Financial Services LLC bought a new position in shares of Ginkgo Bioworks during the second quarter valued at approximately $70,000. Pine Valley Investments Ltd Liability Co lifted its stake in Ginkgo Bioworks by 653.7% in the second quarter. Pine Valley Investments Ltd Liability Co now owns 220,607 shares of the company's stock worth $74,000 after acquiring an additional 191,336 shares during the period. Finally, North Star Asset Management Inc. boosted its holdings in Ginkgo Bioworks by 162.6% in the second quarter. North Star Asset Management Inc. now owns 231,100 shares of the company's stock valued at $77,000 after acquiring an additional 143,100 shares in the last quarter. 78.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on DNA shares. TD Cowen upped their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 20th. BTIG Research lifted their price objective on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a research report on Friday, August 23rd. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $4.58.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock traded up $0.36 during trading on Tuesday, hitting $11.06. The company's stock had a trading volume of 1,102,229 shares, compared to its average volume of 1,160,538. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $75.20. The firm has a market capitalization of $635.43 million, a P/E ratio of -0.85 and a beta of 1.17. The business's fifty day moving average price is $8.28.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.